Information for Investigators/Study Coordinators Overview

 

Clinical Trials being conducted at KU Medical Center


Clinical Research Policies

Effective January 2, 2006: All human subject cancer or cancer-related protocols (therapeutic/treatment, prevention, ancillary/companion and correlative), must be reviewed, approved, and monitored by the Kansas Masonic Cancer Research Institute's Protocol Review and Monitoring Committee (PRMC). PRMC approval must be obtained prior to the Principal Investigator beginning the submission process to the Human Subjects Committee (HSC). Monitoring of the ongoing research will take place after all compliance approvals have been completed.

Scientific Review and Monitoring of Cancer or Cancer- Related Protocols and Research Policy (PDF)


Investigational Drug Dispensing


Investigation Device Exemptions (IDE)


Investigational New Drug (IND) Information

Last modified: May 13, 2013
ID=x1777